Amyloid tends to deposit in the gastrointestinal tract, which, being easily accessible, is often the target organ for a pathological diagnostic examination. Although a mucosal biopsy is necessary for a definitive diagnosis and several studies have reported positive results for each possible biopsy site, there remain many unclear features in various aspects. This review focuses on the current literature to determine a better understanding of the diagnosis from endoscopic and histological views in patients with systemic amyloidosis with gastrointestinal involvement. A literature search was performed using PubMed to identify relevant studies; linked references were also reviewed. Endoscopic findings vary based on the organ and the depositing amyloids. A fine granular appearance or polypoid protrusions are likely to occur in the duodenum. AL, Aβ2M, and ATTR amyloids are likely to deposit submucosally, while AA amyloid is easily deposited in the superficial layer of the mucous membrane. Furthermore, it is necessary to consider the collection of biopsy specimens from the duodenum, which has high positive biopsy rates. However, the difference in the positive biopsy rates depends on whether endoscopic findings are available or whether the appropriate number has not been fully elucidated. A duodenal biopsy is strongly recommended to confirm the deposition of amyloid in patients with systemic amyloidosis having gastrointestinal involvement. Because amyloidosis is a disease with a poor prognosis, early diagnosis and treatment are required; gastroenterologists and endoscopists play important roles.
Introduction
Amyloidosis is a group of diseases caused by extracellular deposition of amyloid fibrils leading to organ dysfunction. Amyloid consists of misfolded, insoluble, toxic peptide aggregates, which are oriented in a β-sheet structure. Using electron microscopy, amyloid fibrils appear to be under 10 nm in diameter; using polarized light microscopy, the regular structure of the fibrils leads to apple-green birefringence following staining with Congo red dye. 1 To date, at least 31 different human proteins have been identified as amyloidogenic, causing both systemic and localized disease. 2 The classification suggested by the International Symposium on Amyloidosis is simplified and shown in Table 1 . Patients with systemic amyloidosis (SA) inevitably have amyloid precursor proteins in the blood; conversely, the precursor proteins in patients with localized amyloidosis are generated locally, only in the areas where the lesions develop and are not contained in the blood. SA directly affects patient prognosis. The most common form of SA is primary (amyloid light-chain [AL] ) amyloidosis, which is related to plasma cell dyscrasia and the accumulation of light-chain amyloid fibrils in multiple organs. 3 AL amyloidosis can be classified into primary amyloidosis and myelomaassociated amyloidosis depending on whether myeloma is present. Secondary amyloidosis is associated with the deposition of serum amyloid A (AA) protein, which is an acute-phase reactant protein produced during chronic inflammatory or infectious diseases, such as rheumatoid arthritis, Crohn's disease (CD), and familial Mediterranean fever. [4] [5] [6] The other forms of SA are classified by the amyloidogenic precursor protein, such as amyloid β2-microglobulin (Aβ2M) and amyloid transthyretin (ATTR). 2 The kidney and heart are the most commonly involved organs in patients with SA, but amyloid tends to deposit in the gastrointestinal (GI) tract, which, being easily accessible, is often the target organ for a pathological diagnostic examination. Although a mucosal biopsy is necessary for a definitive diagnosis and several studies reported the yield of positive results for each possible biopsy site in the past, [7] [8] [9] [10] there remain many unclear features, such as the appropriate number of biopsies for diagnosis and the difference in the yield of positive biopsy results depending on the presence/absence of endoscopic findings.
Endoscopically, it has been reported that the findings of the GI tract are non-specific and include erythema, erosions, ulcerations, granular mucosa of the stomach or small intestine, large duodenal folds, friability, polypoid protrusions, and elevated lesions like submucosal tumors (Fig. S1a-d) .
This review focuses on the current literature to determine a better understanding of diagnosis from endoscopic and histological views in patients with SA with GI involvement.
Pathogenesis
AL amyloidosis. AL amyloidosis is the most common form of amyloidosis. 3, 11 Automated protein analysis of the amino acid sequences reveals that these peptides represent the N-terminal of the variable region of the κ or λ light-chains of the immunoglobulins. 12, 13 The circulating light-chain proteins are called Bence Jones proteins, which are secreted by a plasma-cell clone. AL has been associated with certain plasma-cell dyscrasias, for example, primary amyloidosis, multiple myeloma, and Waldenstrom's macroglobulinaemia. 12, [14] [15] [16] AA amyloidosis. The mechanism of development can be described as follows: The various cytokines involved in chronic inflammation stimulate the liver cells and upregulate the production of serum amyloid A (SAA), resulting in SAA being maintained at high levels. This SAA is transformed into AA through various mechanisms and deposits in the tissues.
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Aβ2M amyloidosis. The fibrils are composed of Aβ2M, possibly retained in the body because of decreased renal clearance. [18] [19] [20] The degree of amyloid deposition depends on the length of dialysis. 19 ATTR amyloidosis. ATTR amyloidosis consists of familial amyloidotic polyneuropathy (FAP) and senile amyloidosis. The amyloid precursor proteins in FAP cases are all in vivo variant proteins and need to be genetically assessed for a definitive diagnosis. The TTR gene variants relating to the onset of FAP are known to include more than 100 kinds worldwide 21 and more than 30 kinds in Japan. The TTR gene variants in younger cases are mostly Val30Met, while many reports have shown non-Val30Met with frequent mutations in elderly cases. Senile amyloidosis has a pathology, in which amyloid deposits in the heart or the large vessel system in the elderly, leading to the development of refractory cardiac failure in clinical settings. Other than cardiac failure, senile amyloidoses are frequently complicated with carpal tunnel syndrome, which is caused by amyloid deposition 22 and is highly likely to develop with the present pathology as the initial symptom. Amyloid is derived from wild-type TTR; this condition develops after the age of 60 years. 23 
Endoscopic findings
Differences in endoscopic findings of systemic amyloidosis with gastrointestinal involvement by organs ( Table 2 ). Esophagus. Among 37 (AL: 8, AA: 29) patients with SA, Tada et al. 7 found abnormalities in the esophagus of 32 (84%) and reported a fine granular appearance in 6 (16%) of them. In one series, esophagogastroduodenoscopy (EGD) was performed in 14 of 19 patients with GI amyloidosis (AL: 19) with malabsorption; esophagitis was observed in two (14%) patients. 24 Other reports include mainly case reports. [25] [26] [27] The endoscopic findings of a mass or an ulceration were reported but were non-specific. As a functional problem, esophageal motility disorder due to amyloidosis has been reported sporadically. 26, 27 Costigan and Clouse 26 reported that upper endoscopy in patient with AL amyloidosis revealed a convergence of normal-appearing folds in the distal esophagus, which opened with gentle pressure. Moreover, Suris et al. 27 reported cases of achalasia of the esophagus among AA amyloidosis patients found to have stenosis in the distal esophagus. Endoscopic views of systemic amyloidosis T Iida et al. 7 found no abnormality in the stomach of 11 (30%) of the 37 patients mentioned previously, investigators reported the presence of multiple erosions in 23 (62%) and a fine granular appearance in 13 (35%). Upper GI endoscopic findings in 14 patients who had been histologically diagnosed with AL amyloidosis revealed that gastritis, gastric ulcer, and increased gastric residual were seen in three (21%), one (7%), and one (7%) patients, respectively. 24 Said et al. 28 reported the study results of 79 patients (AL: 53, AA: 7, ATTR: 14, apolipoprotein A1: 5) with gastric amyloidosis. In this study, endoscopic findings included erythema (26/79: 33%), erosions (14/79: 18%), nodularity (12/79: 15%), and normal (29/79: 35%), and these findings were not related to amyloid type.
Here, we describe the endoscopic findings of the patients with SA who were diagnosed with GI involvement at our facility (AL/AA: 32/4, EGD/colonoscopy [CS]: 31/19) as follows: depressed lesion (14/31: 45%), redness (10/31: 32%), edema (9/31: 29%), mucosal friability (8/31: 26%), elevated lesion like submucosal tumor (8/31: 26%), and normal (14/31: 45%) (including duplicates, Table 3 ).
Duodenum. Tada et al.
7 reported that 26 of 37 patients (70%) with GI amyloidosis had a fine granular appearance and polypoid protrusions in their duodenum. Hayman et al. 24 reported that four of 14 patients (29%) with GI amyloidosis had a duodenitis. It is well known that amyloidosis is one of the complications in patients with CD. Miyaoka et al. 32 focused on the effect of amyloid deposition in the GI tract on endoscopic findings of CD and reported the characteristics of endoscopic findings such as granular elevations or irregular Kerckring's folds, in cases with severe deposition, and coarse mucosa, in cases with mild deposition. Other reports primarily include case reports. 33, 34 The endoscopic findings of multiple polypoid protrusions or thickening of the folds were reported.
In our facility, the endoscopic findings of the duodenum in patients with SA were redness (4/31: 13%), edema (4/31: 13%), white granular mucosa (3/31: 10%), and normal (24/31: 77%) (including duplicates, Table 3 ).
Jejunum and ileum. A small number of studies have examined the endoscopic findings of amyloidosis in the jejunum and ileum; such findings were presented mainly in case reports of localized amyloidosis. Rosenvinge et al. 35 reported a case that capsule endoscopy (CE) and balloon-assisted enteroscopy showed numerous submucosal nodules and mucosal polyps. Choi et al. 36 reported a case that EGD, push enteroscopy, and CE revealed submucosal tumor-like lesions, multiple shallow ulcers, and several erosions in the distal duodenum and jejunum. Submucosal hematomas 37 and scalloping of the valvulae conniventes 38 are some of the small bowel amyloidosis lesions complicated with SA and are diagnosed by small bowel endoscopy. In addition, small bowel lesions with SA found by small bowel CE to be mixed with mucosal hematoma, thickened folds, and stenosis have also been reported. 39 In our facility, the endoscopic findings of the ileum in patients with SA were redness (3/19: 16%), edema (3/19: 16%), stricture (3/19: 16%), elevated lesion like submucosal tumor (3/19: 16%), and normal (13/19: 68%) (including duplicates, Table 3 ). However, these also include patients for whom the ileum terminal alone was observed during the CS. In this regard, we must acknowledge that the calculated percentage of small bowel lesions might be lower than the actual value, because the small intestine of all patients was not endoscopically observed throughout.
Colon and rectum. The manifestations involving the large intestine, as related to amyloidosis, are variable. Among the 37 patients mentioned previously, Tada et al. 7 reported no abnormality in the colon of 16 (43%) but a fine granular appearance in 12 (32%), erosion in 4 (11%), ulcers in 3 (8%), and mucosal friability in 3 (8%). In one series, for nine of 19 AL GI amyloidosis patients performed CS, revealing polyps in two, inflammation or colitis in five, and a normal finding in three. 24 Cho et al. 40 reported a case of hemorrhagic bullous colitis in a patient with multiple myeloma. Kim et al. 41 reported a case of secondary intestinal amyloidosis presenting intractable hematochezia. Furthermore, Kon et al. 42 reported a case presenting multiple submucosal hematomas on CS.
Our data showed that the endoscopic findings of the ileum in patients with SA described previously were indistinct vascular pattern (7/19: 37%), redness (6/19: 32%), edema (6/19: 32%), submucosal hematoma: (4/19: 21%), and normal (9/19: 47%) (including duplicates, Table 3 ).
In any organ, it is noteworthy that normal appearance mucosa was observed with a high proportion despite amyloid deposition; thus, a biopsy should be performed in the case of suspected amyloidosis, even if no abnormal findings are noted.
Differences in endoscopic findings of systemic amyloidosis with gastrointestinal involvement by types of amyloid deposition (Table 4) . AL and AA amyloidosis. The site of amyloid deposition in the GI tract varies depending on the kind of amyloid. Generally, amyloid deposition in the GI tract is different between AL and AA. 43 The former deposits in the submucosal layer and/or muscularis propria as a mass (Figure S2a) , while the latter deposits on the lamina propria 
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mucosae and submucosal layer in a macular or perivascular form ( Figure S2b) ; AA can lead to endoscopically visible mucosal lesions more easily than AL. In AL amyloidosis, polypoid protrusions and thickening of the folds are seen. On the other hand, in AA amyloidosis, fine granular appearance and mucosal friability are the typical findings. 44 Our data revealed less endoscopic findings than reported previously. 7 We speculate that the reason for this difference may be related to the type of deposited amyloids. In fact, Tada et al. 7 reported that six of 37 cases were AL, and the remaining 31 were AA, while our data showed that 28 of 32 cases were AL, and the remaining four were AA. Aβ2M amyloidosis. Aβ2M has an affinity for the constituent tissues of the bone and joint; however, the examination of biopsy cases revealed frequent depositions in the GI tract as well (at 80%). The frequency and degree of deposition were not different among the stomach, small intestine, and large intestine. The most common site of deposition was the vascular walls in the submucosal layers, and the frequency decreased in the following order: proper muscular layer, subserosal layer, and muscularis mucosae. The endoscopic findings included multiple gastric and duodenal erosions as well as redness, each of which was non-specific and, thus, did not lead to the diagnosis of amyloidosis. The conceivable reasons for such poor specific findings were that Aβ2M hardly deposits in the mucosal layers, and when it deposits in the submucosal layer, it does mainly in the vascular walls, not as a mass. Aβ2M also deposits mostly in the proper muscular layer even after disease progression. [18] [19] [20] ATTR amyloidosis. ATTR was reported to deposit in the GI tract as well at a frequency of~40%. 45 According to some reports, ATTR deposits in the vascular walls in the submucosal layers, proper muscular layer, and subserosal layer in the GI tract but not in the lamina propria. 46 In FAP, endoscopic findings of the GI tract are mostly a mild, fine granular appearance, and the amount of amyloid deposition in the mucosa is small compared with that in AL and AA amyloidosis. However, a significant amount of deposition is evident in the nerves of the GI tract, which may cause severe diarrhea and malabsorption occasionally observed in FAP patients despite mild macroscopic findings. 47 Cases of patients with ATTR were limited. 48, 49 As described previously, the endoscopic findings of GI amyloidosis vary by the organ and depositing amyloid, showing various features, making it difficult to obtain specific findings. However, we should keep in mind that fine granular appearance or polypoid protrusions are likely to be noted in the duodenum. Further, AL, β2M, and ATTR amyloids are likely to deposit submucosally, while AA amyloid tends to deposit in the superficial layer of the mucous membrane.
Biopsy findings
Differences in positive rate of endoscopic biopsy of systemic amyloidosis with gastrointestinal involvement (Table 5) . Previous studies showed the degree of amyloid deposition and frequency of endoscopic findings in the GI tract. Tada et al. 7 reported that in 37 patients with SA involving the GI tract, the frequency of amyloid deposition in the biopsy specimens was 100% in the duodenum, 95% in the stomach, 91% in the colorectum, and 72% in the esophagus. Cowan et al. 8 examined the utility of GI tract endoscopy in the diagnosis of SA symptoms in 60 people (AL: 50, ALys: 5, ATTR: 5). For patients with AL amyloidosis, the frequency of amyloid deposition in the biopsy specimens was 50% in the small bowel, 44% in the stomach, and 32% in the colon. Furthermore, Lim et al.
9 investigated 24 patients with SA involving the GI tract (AL: 20, AA: 3, ATTR: 1) and reported that the frequency of amyloid deposition in the biopsy specimens was 55% in the stomach, 45% in the colon, 35% in the rectum, and 5% in the duodenum. In recent years, Freudenthaler et al. 10 reported 542 patients with SA involving the GI tract (AL: 360, AA: 58, ATTR: 88, Others: 36) and reported that the frequency of amyloid deposition in the biopsy specimens was 38% in the colon, 23% in the stomach, 17% in the rectum, 16% in the duodenum, and 6% in the jejunum or ileum. Furthermore, the results of the autopsy on 73 patients with amyloidosis (AL: 20, AA: 53) by Briggs 50 demonstrated that the highest and the lowest frequency of amyloid deposition in the biopsy specimens was in the small intestine (43%) and stomach (23%). Yilmaz et al. 51 investigated 65 patients with AA amyloidosis and reported that the frequency of amyloid deposition in the biopsy specimens was 98% in the duodenum, 78% in the rectum, 77% in the antrum, and 52% in the esophagus.
Regarding our data in 36 patients with amyloidosis involving the GI tract, the frequency of amyloid deposition in the biopsy specimens was 86% in the rectum, 85% in the duodenum, 73% in the colon, 65% in stomach, and 38% in the ileum or jejunum. In summary, we found the frequency of amyloid deposition in each part of the GI tract (stomach, duodenum, small intestine, and colon) varied depending on the patients' background and types of amyloidosis. Nevertheless, the duodenum might be an appropriate site for the endoscopic biopsy for diagnosis, because the positivity of amyloid deposition was the highest in duodenum among other sites of the GI tract.
Differences in the presence or absence of endoscopic findings and the number of biopsies. Despite previous studies on the yield of positive biopsy results from different sites, there has been no study regarding the appropriate number of biopsies for diagnosing GI amyloidosis. Therefore, in this section, we present data regarding the appropriate location, including the yield of positive biopsies related to the endoscopic findings, and the appropriate number of biopsies in our facility.
As described previously, the number of subjects was 36 (AL: 32/AA: 4). Biopsy samples were taken from the intestinal mucosa with endoscopic features such as redness, edema, submucosal tumor-like swelling, and from normal appearance mucosa. The positive biopsy rate was defined as the proportion of amyloid deposits among all biopsy numbers in each organ. Moreover, we investigated the number of biopsies for positive/negative results and the yield of positive biopsy results with the presence/absence of endoscopic findings for each organ, retrospectively.
In the diagnostic yield of biopsies from the stomach, there was a significant difference in the mean number of positive and negative biopsy cases for amyloid deposition (2.8 vs. 1.5, P = 0.02). On the contrary, no significant difference was observed between positive and negative cases for amyloid deposition in the duodenum (1.7 vs. 1.3, P > 0.05), ileum (1.7 vs. 1.0, P > 0.05), colon (4.2 vs. 2.0, P > 0.05), or rectum (1.7 vs. 1.0, P > 0.05).
The percentage of positive biopsy results in the stomach was significantly higher in GI amyloidosis patients with endoscopic findings than in those without such findings (80% vs. 44%, P = 0.02). Additionally, a similar tendency was observed in the colon (88% in patients with endoscopic findings vs. 42% in those without such findings; P = 0.02). On the contrary, in the duodenum, no significant difference in the percentage was observed between patients with endoscopic findings than in those without such findings (stomach: 89% vs. 90%; P = 0.96, rectum: 88% vs. 78%; P = 0.60) ( Table 6) .
Taken together, our study demonstrated that the yield of positive biopsy results in the duodenum and rectum was high regardless of the number of biopsies or existence of endoscopic findings. However, the yield of positive biopsy results in the stomach was lower than that in other sites and was even lower in cases with no endoscopic findings in the stomach. In addition, the number of biopsies from the stomach affected the positive biopsy results, suggesting that at least more than three biopsies from the stomach would be required for diagnosis of GI involvement. In the colon and stomach, the existence of endoscopic findings was associated with positive biopsy results.
The risk of gastrointestinal bleeding in gastrointestinal amyloidosis. Intestinal bleeding may easily occur in patients with GI amyloidosis because of blood vessel wall injury and vulnerability of intestinal mucosa induced by amyloid deposition. [52] [53] [54] [55] Therefore, it is possible that an increasing number of biopsy specimens for increasing diagnostic yield for GI amyloidosis could increase the risk of intestinal bleeding. Thus, a small number of biopsy specimens, as much as possible, from the sites of the GI tract are appropriate to reduce the risk of GI bleeding. In our AA, amyloid A; AL, amyloid light-chain; ATTR, amyloid transthyretin; GI, gastrointestinal; ND, not described.
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facility, one of 36 (2.8%) patients with SA with GI involvement had post-biopsy bleeding. However, until now, the rate of bleeding after biopsy in patients with SA with GI involvement has not been discussed in detail. Given the results of the present and the previous studies, we recommend the biopsy from the duodenum. However, there remains a lack of sufficient reports on the endoscopic or pathological biopsy findings of amyloidosis, or particularly, on the appropriate site and the number of biopsies. Detailed investigations with more cases should be performed in the future.
Conclusion
Amyloidosis is a systemic disease that targets the GI tract. Various endoscopic findings can be observed on the basis of the organ and depositing amyloid; it should be noted that a fine granular appearance or polypoid protrusions is likely to occur in the duodenum. AL, β2M, and ATTR amyloids are likely to deposit submucosally, while AA amyloid is prone to deposit in the superficial layer of the mucous membrane. Because amyloidosis is a disease with a poor prognosis, early diagnosis and treatment are required, in which gastroenterologists and endoscopists can play major roles. To achieve early diagnosis, it is necessary to consider collection of biopsy specimens from the duodenum, which have high positive biopsy rates. However, a further examination and discussion are needed pertaining to the difference in positive biopsy rates depending on whether endoscopic findings are available, or on the appropriate number of biopsy samples.
